Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. monthly Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E15.91 EPS (ttm)4.21 Insider Own0.54% Shs Outstand1.27B Perf Week0.07%
Market Cap84.89B Forward P/E10.51 EPS next Y6.37 Insider Trans-1.92% Shs Float1.26B Perf Month6.98%
Income5.39B PEG11.73 EPS next Q1.56 Inst Own84.00% Short Float1.64% Perf Quarter4.22%
Sales22.45B P/S3.78 EPS this Y-45.60% Inst Trans0.09% Short Ratio2.10 Perf Half Y5.61%
Book/sh16.26 P/B4.12 EPS next Y-1.19% ROA9.60% Target Price75.00 Perf Year0.03%
Cash/sh18.04 P/C3.71 EPS next 5Y1.36% ROE27.50% 52W Range60.89 - 71.19 Perf YTD3.11%
Dividend2.72 P/FCF19.79 EPS past 5Y18.10% ROI12.00% 52W High-2.64% Beta1.27
Dividend %4.06% Quick Ratio2.90 Sales past 5Y14.60% Gross Margin79.20% 52W Low13.83% ATR1.55
Employees11000 Current Ratio3.00 Sales Q/Q0.10% Oper. Margin37.60% RSI (14)62.76 Volatility1.49% 2.35%
OptionableYes Debt/Eq1.19 EPS Q/Q-157.30% Profit Margin26.50% Rel Volume2.09 Prev Close67.00
ShortableYes LT Debt/Eq1.07 EarningsFeb 04 AMC Payout51.60% Avg Volume9.83M Price69.31
Recom2.40 SMA204.78% SMA505.44% SMA2005.92% Volume14,712,034 Change3.45%
Feb-06-20Downgrade Bernstein Outperform → Mkt Perform $78 → $70
Feb-05-20Downgrade Raymond James Strong Buy → Outperform $81 → $80
Jan-21-20Downgrade Guggenheim Buy → Neutral
Dec-13-19Downgrade Credit Suisse Neutral → Underperform $67 → $63
Nov-12-19Initiated SunTrust Hold $70
Oct-25-19Downgrade Maxim Group Buy → Hold
Oct-17-19Resumed BofA/Merrill Neutral $70
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Feb-20-20 01:19PM  WHO Urges Nations to Increase Funding: Virus Update Bloomberg
07:44AM  Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 23%? Simply Wall St.
Feb-19-20 02:51PM  3 Contrarian Stocks to Buy Now for Absolute Returns InvestorPlace
10:29AM  Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake American City Business Journals
10:00AM  Is Gilead Stock A Buy As It Takes Aim At The Deadly Coronavirus? Investor's Business Daily
08:30AM  Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Companys External Innovation Center Business Wire
07:23AM  What Apple, Walmart and other U.S. companies are saying about the coronavirus outbreak MarketWatch
Feb-18-20 08:00PM  Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 Business Wire
01:01PM  The Wuhan Virus and Research-Focused Biotech Companies
Feb-14-20 09:02AM  Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy.
08:22AM  Gilead Sciences Stock at Cusp of New Uptrend Investopedia
Feb-13-20 05:35PM  Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials Reuters
Feb-12-20 04:30PM  Results from Chinese drug trials for coronavirus due in weeks -expert Reuters
03:48PM  China Keeps Experts Waiting; Conference Canceled: Virus Update Bloomberg
05:41AM  Chinese Firm Makes Gilead Drug in Virus Fight, Raising IP Fears Bloomberg
Feb-11-20 05:27PM  Can Biotech ETFs Gain on Mixed Q4 Earnings Results? Zacks
02:18PM  Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine MarketWatch
09:12AM  Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance Zacks
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 09:37AM  New Strong Sell Stocks for February 10th Zacks
08:30AM  U.S. FDA Grants Priority Review for Kites KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma Business Wire
12:00AM  Coronavirus sparks hectic trading in search of treatment Financial Times
Feb-08-20 08:00AM  Prudential Financial, Gilead, and 3M Raised Dividends Last Week
Feb-07-20 05:35PM  As coronavirus infections surge, Bay Area offers a possible drug, diagnostic and advice American City Business Journals
04:22PM  Coronavirus update: Business impact widens as China fights to get infections under control Yahoo Finance
04:06PM  No Glitches in Early Effort for Coronavirus Vaccine, NIH Says. Moderna Stock Is Flying.
01:21PM  4 Internet Stocks to Buy That Are Surging Higher InvestorPlace
12:18PM  Edited Transcript of GILD earnings conference call or presentation 4-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
07:11AM  The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences Zacks
07:07AM  3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare InvestorPlace
Feb-06-20 05:50PM  Can Biotech ETFs Continue to Soar in 2020? Zacks
12:55PM  Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates Zacks
10:04AM  Company News for Feb 6, 2020 Zacks
Feb-05-20 04:20PM  S&P 500, Nasdaq close at records amid upbeat data, easing coronavirus fears MarketWatch
03:19PM  FOCUS-Drugmakers see long road ahead in coronavirus vaccine race Reuters
12:19PM  Chinas Drug Patent Grab Makes Coronavirus Scary for Pharma Bloomberg
11:17AM  Regeneron Expands Agreement to Develop Coronavirus Therapy Zacks
11:15AM  Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks
10:31AM  Gilead Stock Is Falling After a Disappointing Earnings Report
09:40AM  Gilead Falls Post-Earnings but China Wants to Patent Its Coronavirus Drug
09:24AM  China lab seeks patent on use of Gilead's coronavirus treatment Reuters
09:21AM  Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:09AM  Gilead Could Hold the Key to Treating the Coronavirus
09:05AM  Market Morning: Intel Goes Smart, Amazon Keeps Climbing, Coronavirus Delays Trade Deal Market Exclusive
07:43AM  The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap Zacks
07:03AM  Top 5 Things to Know in the Market on Wednesday, 5th February
02:10AM  China lab seeks patent on use of Gilead's coronavirus treatment Reuters
12:19AM  StockBeat: Markets Surge on Hints of Virus Drugs; Smurfit, Vestas Soar
Feb-04-20 06:31PM  Disney, Gilead & Snap Post Mixed Quarters, Chipotle Beats Zacks
05:15PM  This Biotech Giant Just Slipped On Its Mixed Fourth-Quarter Report Investor's Business Daily
05:15PM  Gilead Sciences (GILD) Misses Q4 Earnings Estimates Zacks
04:45PM  Gilead 4th-quarter profit, 2020 outlook fall short of Street view Reuters
04:14PM  Gilead stock slips as earnings, outlook miss Street view MarketWatch
04:02PM  Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend Business Wire
04:01PM  Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results Business Wire
12:27PM  A Pick and Shovel Strategy to Avoid Competition and Speculation
11:04AM  Gilead Earnings Miss, Revenue Beats In Q4
10:20AM  Company News for Feb 4, 2020 Zacks
09:02AM  Gilead Wont Profit Off Coronavirus, Analyst Says. Buy the Stock Anyway.
09:00AM  Why hedge fund manager Dan Loeb is staying wary of this too-perfect market MarketWatch
05:28AM  Stocks - Tesla Flies as Wall Street Surges on Fresh Optimism
01:31AM  Top 5 Things to Know in the Market on Tuesday, 4th February
Feb-03-20 05:01PM  The Dow Rose 144 Points Because the Whole World Is Fighting the Coronavirus
04:42PM  Stocks end higher as Wall Street turns focus to positive data MarketWatch
04:26PM  CDC Readies for Pandemic; Long Vaccine Timeline: Virus Update Bloomberg
04:18PM  Biotech Giant Surges On Plan To Test Coronavirus Drug In Humans Investor's Business Daily
02:44PM  US Markets Advance on Monday
02:25PM  Gileads antiviral is encouraging as coronavirus candidate but isnt likely to provide long-term shareholder value MarketWatch
02:17PM  Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS MarketWatch
01:55PM  Gilead Could Post Huge Breakout on Coronavirus Treatment
01:23PM  Dow Rises and Oil Slumps as Focus Remains on Coronavirus Impact on Global Growth
01:06PM  Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks
12:46PM  The Dow Is Up 250 Points as Stocks Are Bouncing Back From Fridays Fall
12:32PM  PreMarket Prep Recap: Bulls Regain Early Control Of The Markets Benzinga
12:19PM  US STOCKS-Wall Street rises as U.S. manufacturing expands in January Reuters
12:15PM  Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout
12:01PM  Gilead Drug to Undergo Human Trials in China to Cure Coronavirus Bloomberg
10:41AM  US STOCKS-Wall Street rebounds as U.S. manufacturing expands in January Reuters
10:16AM  Gilead Might Have a Coronavirus Treatment. Its Stock Is Rising.
09:40AM  Gilead Surges After Offering Experimental Coronavirus Drug for Testing in China
09:19AM  Gilead's Experimental Antiviral Drug To Be Screened In Human Trials In China For Coronavirus Benzinga
09:12AM  US STOCKS-Wall Street set to open higher after steep selloff Reuters
08:39AM  Should You Buy Gilead (GILD) Ahead of Earnings? Zacks
08:04AM  Gilead's stock jumps 5% on coronavirus treatment plans MarketWatch
07:53AM  US STOCKS-Futures point to rebound as China seeks to curb virus impact Reuters
06:54AM  Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing? Zacks
03:25AM  Stocks - Apple Falls in Premarket; Drug Reports Lift Gilead, AbbVie
Feb-02-20 04:08PM  China Vows to Support Market, U.S. Limits Flights: Virus Update Bloomberg
08:00AM  Gilead, Prudential, and Corning Are Expected to Boost Their Dividends
Feb-01-20 08:14PM  Stocks That Fell to 3-Year Lows in the Week of Jan. 31
Jan-31-20 02:01PM  Gilead working with China to test Ebola drug as new coronavirus treatment Reuters
09:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings? Zacks
Jan-30-20 06:21PM  J&J (JNJ) Plans to Develop Vaccine for New Coronavirus Zacks
04:05PM  Sandra Horning, MD, Joins Gilead Sciences Board of Directors Business Wire
10:54AM  These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus
10:35AM  'It's not worth the gamble': Wuhan coronavirus shifts Bay Area companies' plans in China American City Business Journals
05:10AM  Roche says closed Chinese cities hinder virus diagnostics test deliveries Reuters
Jan-29-20 10:06AM  Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation Zacks
09:59AM  Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-28-20 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; Carna Biosciences Inc.; and Glympse Bio, Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM